Cargando…
Monitoring prolongation of QT interval in patients with multidrug-resistant tuberculosis and non-tuberculous mycobacterium using mobile health device AliveCor
Multidrug resistant tuberculosis and non-tuberculous mycobacterium infections present challenges due to complex treatment regimens. Extended treatment regimes expose patients to higher risks of toxic side-effects. A high drug toxicity profile necessitates closer monitoring. One of the more challengi...
Autores principales: | Puranik, Shriya, Harlow, Christopher, Martin, Laura, Coleman, Meg, Russell, Georgina, Park, Mirae, Min Kon, Onn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802120/ https://www.ncbi.nlm.nih.gov/pubmed/35146132 http://dx.doi.org/10.1016/j.jctube.2021.100293 |
Ejemplares similares
-
Effectiveness of a single lead AliveCor electrocardiogram application for the screening of atrial fibrillation: A systematic review
por: Hall, Angela, et al.
Publicado: (2020) -
Recurrent atrial fibrillation/flutter detection after ablation or cardioversion using the AliveCor KardiaMobile device: iHEART results
por: Goldenthal, Isaac L., et al.
Publicado: (2019) -
Single-lead ECGs (AliveCor) are a feasible, cost-effective and safer alternative to 12-lead ECGs in community diagnosis and monitoring of atrial fibrillation
por: Bray, Jonathan James Hyett, et al.
Publicado: (2021) -
Improving the utility and sustainability of novel health technology to improve clinical outcomes for patients: an East Staffordshire experience of screening for atrial fibrillation with the AliveCor KardiaMobile
por: Mathew, Savio, et al.
Publicado: (2021) -
Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study
por: Ellins, Elizabeth A, et al.
Publicado: (2023)